Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classificação em ações #4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Preço da ação
$27.18
Última sincronização: 2026-07-31
Valor de mercado
$3.38B
Variação (1 dia)
-1.41%
Variação (1 ano)
202.34%
País
US
Negociar Tango Therapeutics, Inc. (TNGX)

Categoria

Healthcare
Rácio P/S de Tango Therapeutics, Inc. (TNGX)
Rácio P/S em October 2026 TTM: 67.14
De acordo com os relatórios financeiros mais recentes e o preço das ações da Tango Therapeutics, Inc., o rácio P/S atual (TTM) é 67.14. No final de 2023, o rácio P/S era 25.63.
Histórico do rácio P/S da Tango Therapeutics, Inc. de 2019 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
2026 (TTM) 67.14 737.15%
2024 8.02 -68.70%
2023 25.63 0.08%
2022 25.61 39.62%
2021 18.34 -61.56%
2020 47.71 1,179.46%
2019 3.73 0.00%
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
10.02 -85.07%
US
40.55 -39.60%
US
3.96 -94.10%
AU
- -
CH
10.15 -84.89%
NL